Iordanis Gravanis1, Stella E Tsirka. 1. Stony Brook University, Department of Pharmacological Sciences, Stony Brook, NY 11794-8651, USA.
Abstract
BACKGROUND: Ischemic stroke is a leading cause of morbidity and mortality worldwide and recombinant human tissue-type plasminogen activator (tPA) is the prominent therapeutic among very few therapeutics used in its treatment. Due to complications attributed to the drug, most notably transformation of ischemia to hemorrhage, tPA is only used in a small number of ischemic stroke cases, albeit significantly more often in specialized stroke centers. OBJECTIVE: What are the mechanisms of tPA action and side effects in ischemic stroke, and can the knowledge about these mechanisms aid in making tPA a more efficacious and safe therapeutic or in developing alternative therapeutics? METHODS: tPA use and alternative/combination therapies in acute ischemic stroke treatment are summarized. The review focuses on literature concerning tPA neurotoxicity and its implications for further development of tPA as a stroke therapeutic. RESULTS/ CONCLUSION: Exogenously administered recombinant tPA and endogenous tPA have both turned into promising therapeutic targets for the stroke patient.
BACKGROUND:Ischemic stroke is a leading cause of morbidity and mortality worldwide and recombinant humantissue-type plasminogen activator (tPA) is the prominent therapeutic among very few therapeutics used in its treatment. Due to complications attributed to the drug, most notably transformation of ischemia to hemorrhage, tPA is only used in a small number of ischemic stroke cases, albeit significantly more often in specialized stroke centers. OBJECTIVE: What are the mechanisms of tPA action and side effects in ischemic stroke, and can the knowledge about these mechanisms aid in making tPA a more efficacious and safe therapeutic or in developing alternative therapeutics? METHODS:tPA use and alternative/combination therapies in acute ischemic stroke treatment are summarized. The review focuses on literature concerning tPAneurotoxicity and its implications for further development of tPA as a stroke therapeutic. RESULTS/ CONCLUSION: Exogenously administered recombinant tPA and endogenous tPA have both turned into promising therapeutic targets for the strokepatient.
Authors: Rebecca M Sugg; Jennifer K Pary; Ken Uchino; Sarah Baraniuk; Hashem M Shaltoni; Nicole R Gonzales; Robert Mikulik; Zsolt Garami; Sandi G Shaw; Dawn E Matherne; Lemuel A Moyé; Andrei V Alexandrov; James C Grotta Journal: Arch Neurol Date: 2006-08
Authors: P Cinelli; R Madani; N Tsuzuki; P Vallet; M Arras; C N Zhao; T Osterwalder; T Rülicke; P Sonderegger Journal: Mol Cell Neurosci Date: 2001-11 Impact factor: 4.314
Authors: Sa'ed Akkawi; Taher Nassar; Mark Tarshis; Douglas B Cines; Abd Al-Roof Higazi Journal: Am J Physiol Heart Circ Physiol Date: 2006-02-17 Impact factor: 4.733
Authors: Bethany D Sanders; Melissa G Davis; Sharon L Holley; Julia C Phillippi Journal: J Midwifery Womens Health Date: 2018-01-25 Impact factor: 2.388
Authors: Zhongwu Liu; Yi Li; Li Zhang; Hongqi Xin; Yisheng Cui; Leah R Hanson; William H Frey; Michael Chopp Journal: Neurobiol Dis Date: 2011-11-15 Impact factor: 5.996
Authors: Hyesook Yoon; Sachiko I Blaber; D Michael Evans; Julie Trim; Maria Aparecida Juliano; Isobel A Scarisbrick; Michael Blaber Journal: Protein Sci Date: 2008-08-12 Impact factor: 6.725